10-Q: Sigyn Therapeutics Faces Going Concern Doubt Amid Losses, Board Exits

Sigyn Therapeutics reported increased net losses and a significant cash decline in Q2 2025, raising substantial doubt about its ability to continue as a going concern, compounded by recent board and CSO resignations.

Summary

• Reported a net loss of $2,119,751 for the six months ended June 30, 2025, compared to $1,620,471 for the same period in 2024.
• Cash balance significantly decreased to $459 as of June 30, 2025, from $12,144 at December 31, 2024.
• Accumulated deficit reached $16,801,475 and working capital deficit was $5,487,629 as of June 30, 2025.
• Operating expenses decreased by 17.6% to $1,015,572 for the six months ended June 30, 2025, primarily due to a significant reduction in research and development costs.
• Several convertible notes, including those from Brio Capital and Osher Capital Partners, are in default, though extensions were agreed upon post-period.
• Initiated a Regulation D offering on January 9, 2025, selling 69 units for $379,717 ($345,197 cash received) as of June 30, 2025.
• Three board members and the Chief Scientific Officer resigned in July and August 2025 due to the discontinuation of directors and officers liability insurance.
• Identified material weaknesses in internal controls over financial reporting, including inadequate segregation of duties and lack of comprehensive entity-level controls.

Sentiment

Score: 2

Explanation: The company faces severe financial distress with minimal cash, increasing losses, and a substantial accumulated deficit, leading to a going concern doubt. Multiple debt defaults and the resignation of key personnel due to lapsed D&O insurance highlight significant operational and governance challenges, despite some positive developments in product development and recent capital raises.

Positives

• Operating expenses decreased by 17.6% to $1,015,572 for the six months ended June 30, 2025, compared to $1,232,774 in the prior year, primarily driven by reduced research and development costs.
• Successfully demonstrated the feasibility of Sigyn Therapy administration in eight porcine subjects for xenotransplantation applications.
• Received a Notice of Allowance from the USPTO related to the use of Sigyn Therapeutics, Sigyn Therapy, and protection of the corporate logo, strengthening intellectual property.
• Secured a Convertible Note Purchase Agreement with Lambda Venture Partners, LLC for up to $550,000 in notes, with $100,000 received in the first tranche post-period end, providing additional capital.
• Noteholders Osher and Brio agreed to extend all outstanding notes to December 31, 2027, for an original issue discount totaling $737,786, mitigating immediate default risks on a significant portion of debt.

Negatives

• Net loss increased to $2,119,751 for the six months ended June 30, 2025, from $1,620,471 in the prior year, indicating worsening profitability.
• Cash balance plummeted to $459 as of June 30, 2025, from $12,144 at December 31, 2024, highlighting severe liquidity issues.
• Accumulated deficit grew to $16,801,475 and working capital deficit was $5,487,629 as of June 30, 2025, raising substantial doubt about the ability to continue as a going concern.
• Several convertible notes, including a $44,000 note from Brio and two Brio notes totaling $125,000, and three Osher notes totaling $316,350, matured and are in default.
• Three non-executive board members and the Chief Scientific Officer resigned in July and August 2025 due to the discontinuation of directors and officers liability insurance coverage.
• General and administrative expenses increased to $899,065 for the six months ended June 30, 2025, from $684,406 in the prior year, despite overall operating expense reduction.
• Recognized a loss of $17,505 due to the modification of warrants in June 2025 by adjusting the conversion price from $6.00 to $4.00 per share.

Risks

• Substantial doubt exists about the ability to continue as a going concern due to accumulated deficit, working capital deficit, recurring net losses, and lack of revenue since inception.
• Reliance on raising additional funds through public offerings or asset sales, with no assurance of success or acceptable terms.
• Dependence on third-party organizations for clinical development studies and component suppliers, with potential delays if relationships are interrupted.
• Sigyn Therapy and other therapeutic candidates are classified as Class III medical devices, requiring extensive and costly Pre-Market Approval (PMA) processes from the FDA, with no assurance of approval.
• Competition from medical device or pharmaceutical companies with significantly greater resources could adversely impact market penetration and success.
• Material weaknesses in internal controls over financial reporting, including inadequate segregation of duties and lack of comprehensive entity-level controls, pose risks to financial reporting accuracy.
• The discontinuation of directors and officers liability insurance coverage led to multiple board and executive resignations, potentially impacting governance and future leadership recruitment.

Future Outlook

Management intends to raise additional funds through a public offering or an asset sale transaction to support operations and address the going concern doubt. The company plans first-in-human clinical studies for Sigyn Therapy in ESRD patients and continues to develop its cancer treatment technologies. There is no assurance of FDA approval or market clearance for any of its therapeutic candidates.

Management Comments

• Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern.
• Management believes in the viability of its strategy to generate revenues and in its ability to raise additional funds or transact an asset sale, though there can be no assurances to that effect or on terms acceptable to the Company.
• Management believes that our condensed consolidated financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

Industry Context

Sigyn Therapeutics operates in the highly competitive and capital-intensive medical device sector, focusing on extracorporeal blood purification for infectious diseases and cancer. Its lead candidate, Sigyn Therapy, targets unmet needs in areas like sepsis, endotoxemia in ESRD patients, and xenotransplantation, aligning with growing interest in multi-mechanism therapies for complex conditions. The cancer therapy platforms (ImmunePrep, ChemoPrep, ChemoPure) aim to optimize existing drug benefits, a strategy that could be attractive given the high value of immunotherapeutic antibodies and the FDA's Project Optimus initiative to reduce chemotherapy toxicity. The company's prior experience with FDA Emergency Use Authorization for Ebola treatment positions it with relevant expertise in pandemic response technologies, a critical area in global health.

Comparison to Industry Standards

• The company's accumulated deficit of $16.8 million and cash balance of $459 are significantly below industry averages for development-stage medical device companies, which typically require substantial capital for R&D and clinical trials.
• The reliance on convertible notes and the occurrence of multiple defaults, even with subsequent extensions, indicate a challenging financing environment compared to more established peers like Fresenius Medical Care and DaVita, Inc., which dominate the dialysis industry and have robust capital structures.
• The planned first-in-human clinical studies for Sigyn Therapy in 12-15 ESRD patients are a standard early-stage clinical development step, but the Class III device classification implies a longer and more expensive Pre-Market Approval (PMA) pathway compared to 510(k) cleared devices, similar to other complex medical devices from companies like Terumo BCT or CytoSorbents, Inc. that have received FDA Emergency-Use Authorization for blood purification.
• The resignation of multiple board members and a key executive due to lapsed D&O insurance is a severe corporate governance issue, highly unusual and detrimental compared to industry best practices for public companies, and could deter future investment and talent acquisition.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently involved in any legal proceedings or claims that are believed to have a material adverse effect on the business, financial condition, or operating results.

Related Party Transactions

• Mr. Joyce (CEO) receives an annual base salary of $455,000 plus bonus compensation not to exceed 50% of salary, medical insurance, disability benefits, and one year of severance pay if terminated without cause or due to change in control. The company aims to maintain a 9% beneficial ownership target for Mr. Joyce.
• Dr. Annette Marleau (former CSO) received an annual base salary of $300,000 with automatic 3% annual increases plus bonus compensation not to exceed 40% of salary, medical insurance, disability benefits, and up to six months of severance pay if terminated by the company.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing convertible debt issuances and potential future equity raises. The going concern doubt and increasing losses pose a high risk to investment value. Board and executive resignations may erode confidence.
• **Employees**: The company's precarious financial position and going concern doubt create job insecurity. The resignation of the CSO and board members could impact morale and strategic direction.
• **Creditors**: Several convertible notes are in default, indicating a high risk of delayed or non-payment, although some extensions have been secured. The company's ability to repay debt is highly dependent on future capital raises.
• **Customers/Patients**: Potential future patients could benefit from the development of Sigyn Therapy and cancer treatment devices, but the company's financial instability and regulatory hurdles create uncertainty regarding product commercialization.
• **Suppliers**: May face payment delays or increased scrutiny of credit terms due to the company's weak financial health and working capital deficit.

Next Steps

• Management plans to raise additional funds through a public offering or an asset sale transaction.
• Implement remediation plans for identified material weaknesses in internal controls over financial reporting, including appointing additional qualified personnel and modifying financial controls in fiscal year 2025.
• Conduct first-in-human clinical studies for Sigyn Therapy, planning to enroll 12-15 End-Stage Renal Disease (ESRD) patients.
• Continue to advance Sigyn Therapy toward Pre-Market Approval (PMA) with the FDA.
• Continue development of ImmunePrep, ChemoPrep, and ChemoPure cancer treatment technologies.
• Negotiate restructuring terms for defaulted convertible notes with Brio Capital and Osher Capital Partners.

Key Dates

Recommendation

The company is in a highly distressed financial state, evidenced by a cash balance of only $459, an accumulated deficit exceeding $16.8 million, and a substantial working capital deficit. The explicit 'going concern' doubt, coupled with multiple debt defaults (even with subsequent extensions), signals severe liquidity and solvency issues. The resignation of three board members and the Chief Scientific Officer due to the lapse of D&O insurance is a critical governance failure and a major red flag, indicating a breakdown in fundamental corporate protections and leadership stability. While the company has promising therapeutic candidates and has secured some recent financing, the magnitude of its financial challenges, the high-risk nature of its Class III medical device development pathway, and the significant governance issues make the stock a 'strong sell' for any seasoned investor or institution. The risk of further dilution, potential bankruptcy, or inability to commercialize products far outweighs any speculative upside.

Keywords

Sigyn Therapeutics, SIGY, Medical Devices, Infectious Disease, Cancer Therapy, Blood Purification, Extracorporeal Therapy, Sepsis, End-Stage Renal Disease, Xenotransplantation, Immunotherapy, Chemotherapy, FDA Approval, Clinical Trials, Going Concern, Convertible Notes, Capital Raise, Corporate Governance, Biotechnology, Healthcare